首都医科大学学报 ›› 2010, Vol. 31 ›› Issue (2): 192-196.

• 儿科学专题 • 上一篇    下一篇

儿童Epstein Barr病毒相关性噬血细胞性淋巴组织细胞增生症的回顾性分析

金颖康1, 谢正德2, 杜忠东1, 杨双3, 申昆玲1*   

  1. 1. 首都医科大学附属北京儿童医院感染科;2. 首都医科大学附属北京儿童医院病毒室;3. 首都医科大学附属北京儿童医院血液科
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2010-04-21 发布日期:2010-04-21
  • 通讯作者: 申昆玲

Epstein Barr Virus associated Hemophagocytic Lymphohistiocytosis: A Retrospective Study of 78 Pediatric Cases in the Mainland of China

JIN Ying-kang1, XIE Zheng-de2, DU Zhong-dong1, YANG Shuang3, SHEN Kun-ling1*   

  1. 1. Department of Infection, Beijing Children's Hospital, Capital Medical University; 2. Virology Lab, Beijing Children's Hospital, Capital Medical University; 3. Department of hematology, Beijing Children's Hospital, Capital Medical University
  • Received:1900-01-01 Revised:1900-01-01 Online:2010-04-21 Published:2010-04-21
  • Contact: SHEN Kun-ling

摘要: 目的 总结儿童Epstein-Barr病毒相关性噬血细胞性淋巴组织细胞增生症(Epstein-Barr virus associated hemophagocytic lymphohistiocytosis,EBV-HLH)的临床特征,探讨其预后及死亡危险因素。方法 回顾性分析近5年北京儿童医院78例EBV-HLH病人的临床病历资料,包括年龄、性别、临床表现、实验室资料和预后等,统计学方法采用单因素分析和多因素分析法。结果 EBV-HLH的发病年龄高峰在1~2岁,大部分(70.5%)患者血清EBV核抗原EBNA-IgG阳性。总死亡率为56.7%,其中死亡病人中有12例(30.8%)死于诊断后2月内,多因素分析结果显示:未接受化疗(P=0.002)、发病到诊断时间超过4周(P=0.004),白蛋白水平小于20 g/L(P=0.045)与死亡密切相关。结论 EBV-HLH在儿童中死亡率高、预后差,早期诊断、早期化疗可提高患儿的生存率,同时需积极治疗出血性疾病以减少早期死亡。

关键词: Epstein-Barr病毒, 噬血细胞性淋巴组织细胞增生症, 危险因素

Abstract: Objective To evaluate the clinical features of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis(EBV-HLH) in children and to explore its prognosis and risk factors. Methods A retrospective study was performed on 78 pediatric patients with EBV-HLH who were admitted to Beijing Children's Hospital between 2003 and 2008. All patients' medical records were reviewed and analyzed. For each patient, demographic, clinical, laboratory and outcome information was collected. Statistical evaluation was conducted using multivariate and univariate analysis. Results The age of onset peaked between 1 and 2 years. EBV-HLH occurred mainly in the patients who were positive for IgG antibody to EBV nuclear antigen (70.5%). The overall fatality of the disease was 56.7%. Twelve of the 39 case(30.8%) died rapidly within 2 months after diagnosis. Multivariate analysis revealed that not receiving chemotherapy(P=0.002), ≥4 weeks of illness prior to diagnosis(P=0.004), and albumin levels <20 g/L(P=0.045) significantly predicted an increased risk of death. Conclusion EBV-HLH is a severe disease with a high fatality rate that occurs mainly after EBV reactivation. Early initiation of chemotherapy and timely diagnosis significantly improve survival rate. Practical strategies should focus on reducing the likelihood of early death.

Key words: Epstein-Barr virus, hemophagocytic lymphohistiocytosis, risk factor

中图分类号: